Deals Shaping The Medical Industry, February 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2013 through January 2014.
You may also be interested in...
People have challenged patent listings more than 60 times in the past six years but it is up to new drug application holders to decide whether to revise or delist their submissions.
In meta-analyses of biosimilar switching studies, FDA researchers found “zero difference in the risk of death, serious adverse events, and treatment discontinuations between participants who switched between biosimilars and reference products and participants who did not switch.”
Presenting nine-month financial results, Krka disclosed a new slate of strategic objectives stretching out until 2028 – including a tacit admission that its current EBITDA margin may not be sustainable.